9:00am – 10:45am Session XI: Anti-cancer treatments (Mahvash Tavassoli)

Marion MacFarlane A TRAIL-R1-specific Ligand in combination with Doxorubicin selectively targets Primary Breast Tumour Explants for Apoptosis

Ricky W Johnstone Molecular characterisation of HDAC inhibitor-induced death in a mouse model of acute myeloid leukaemia

Catarina Grandela Strategies to target and eradicate Colon Cancer Stem Cells

Helen M. Beere Inhibition of Hsp90 via 17-DMAG Induces Apoptosis in a p53-Dependent Manner to Prevent Medulloblastoma.

Oliver Hill Treatment of Glioblastoma Multiforme with the CD95-Ligand antagonist APG101

Kerstin Papenfuss ATM-independent TRAIL sensitisation by the ATM-inhibitor KU-55933 reveals a novel mitochondria-independent treatment option for cancer

 

10:45am – 11:15am Coffee Break

11:15am – 12:45pm Session XII: Metabolism, Apoptosis and Cancer (Huseyin Mehmet)

Ceyda Acilan The role of reactive oxygen species on smooth muscle cell apoptosis in thoracic aortic aneurysms

Alfredo Caro-Maldonado Molecular mechanisms of cell death induced by inhibition of the glycolitic metabolism

A. Pradelli Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMPLudivine Kinase activation leading to Mcl-1 block in translation

Poul H.B. Sorensen Dominantly-transforming oncoproteins modulate responses to nutrient deprivation by deregulating eEF2 kinase and translation elongation.

Gemma Robinson Switching from aerobic glycolysis to oxidative phosphorylation modulates tumor cell sensitivity to TRAIL

 

Lunch 12:45pm 2:30pm

EWCD football Cup 3:00pm – 5:30pm

Dinner and Party 7:00pm – END